BRAF and neoplasm: Patients with advanced melanoma were recruited in CheckMate 067 regardless of the tumor’s BRAF status; hence, nivolumab plus ipilimumab combination therapy and nivolumab monotherapy were approved for both BRAF-positive and BRAF-negative melanomas.